CANCER LETT 润色咨询

CANCER LETTERS

出版年份：1975 年文章数：4498 投稿命中率： 开通期刊会员，数据随心看

出版周期：Biweekly 自引率：3.3% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2173638, encodeId=cad121e3638b6, content=大家都是多久收到Proof？接收2周了，还没收到消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=189d5691892, createdName=ms7000000196819746, createdTime=Fri Dec 08 08:16:04 CST 2023, time=2023-12-08, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2207568, encodeId=2525220e5681e, content=审稿速度:1.0<br>偏重的研究方向：肿瘤;耐药<br>经验分享：第一次投cancer letters： 肺癌靶向药方向 2024.04.27 With editor 2024.04.30 Under review 2024.05.26 Required review complete 2024.05.26 Decision in process 2024.05.29 Major revision, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202404/cb60946bd398482cbee0ea0aef57ca2d-aebSZIWD78iz.jpg, createdBy=7b889196222, createdName=bluuna_, createdTime=Fri May 31 01:06:47 CST 2024, time=2024-05-31, status=1, ipAttribution=日本), GetPortalCommentsPageByObjectIdResponse(id=2203640, encodeId=ce3e2203640b4, content=第二次投cancer letters，记录时间<br>05/05/2024 投稿<br>05/07/2024 With editor<br>05/08/2024 Under Review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ce5721017, createdName=ms3000000772221561, createdTime=Thu May 09 11:25:45 CST 2024, time=2024-05-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2195041, encodeId=fda92195041e2, content=偏重的研究方向：肿瘤<br>经验分享：请问大家这个期刊二审一般需要多久呀？我3.22提交的返修稿，今天还是Revision Submitted to Journal的状态。要毕业，有点焦急。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c266511434, createdName=科研小黑, createdTime=Sun Mar 24 17:09:24 CST 2024, time=2024-03-24, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2169383, encodeId=23cb2169383eb, content=审稿速度:1.0<br>偏重的研究方向：肿瘤<br>经验分享：10/21/2023 投稿<br>10/23/2023 改格式<br>10/23/2023 分配3个编辑<br>10/26/2023 Under Review<br>11/07/2023 Required Reviews Completed<br>11/10/2023 Decision in Process<br>11/13/2023 Major Revision 给了1个月修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ce5721017, createdName=ms3000000772221561, createdTime=Sat Nov 18 21:22:58 CST 2023, time=2023-11-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2163363, encodeId=3945216336305, content=偏重的研究方向：肿瘤<br>经验分享：09.24投稿， 10.02修改格式， 10.04 with editor， 10.17 with editor 是不是要凉凉？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1422521109, createdName=124dcee1m79暂无昵称, createdTime=Tue Oct 17 17:10:40 CST 2023, time=2023-10-17, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=921392, encodeId=693192139203, content=审稿速度:1.0<br>偏重的研究方向：白血病<br>经验分享：月初投了一篇，昨晚收到邮件分配稿号，今早登录系统一看，Decision in process，那感觉。。。。太提神了。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200618/4c27fa23bb6a44a49a51871bc8fe6190/d1c485af61c8460ba037d35b90d34b04.jpg, createdBy=e5c95263798, createdName=嚯嚯嚯1971, createdTime=Sat Jan 30 15:57:20 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114616, encodeId=19812114616ba, content=我想问一下注册cancer letters 账号的时候title一栏应该填什么啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13335609339, createdName=ms5000002011942975, createdTime=Tue Feb 14 19:24:48 CST 2023, time=2023-02-14, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2091659, encodeId=19db209165937, content=求助，爱思维尔登录注册界面登录卡死怎么解决，一直注册不了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e83e5631686, createdName=雨落殇殇, createdTime=Mon Oct 03 23:21:05 CST 2022, time=2022-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184614, encodeId=85ed218461406, content=刚投稿，血液肿瘤分子检测方向，不知道在不在期刊领域内；必须要提供推荐的审稿人，所有共同作者均需要邮件链接确认作者身份。提交完了之后很快under review，之后只更新了日期不更新状态。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78c76200857, createdName=195092_8956, createdTime=Mon Jan 29 11:53:34 CST 2024, time=2024-01-29, status=1, ipAttribution=香港)]
    2023-12-08 ms7000000196819746 来自山东省

    大家都是多久收到Proof？接收2周了，还没收到消息。

    1

    展开1条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2173638, encodeId=cad121e3638b6, content=大家都是多久收到Proof？接收2周了，还没收到消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=189d5691892, createdName=ms7000000196819746, createdTime=Fri Dec 08 08:16:04 CST 2023, time=2023-12-08, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2207568, encodeId=2525220e5681e, content=审稿速度:1.0<br>偏重的研究方向：肿瘤;耐药<br>经验分享：第一次投cancer letters： 肺癌靶向药方向 2024.04.27 With editor 2024.04.30 Under review 2024.05.26 Required review complete 2024.05.26 Decision in process 2024.05.29 Major revision, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202404/cb60946bd398482cbee0ea0aef57ca2d-aebSZIWD78iz.jpg, createdBy=7b889196222, createdName=bluuna_, createdTime=Fri May 31 01:06:47 CST 2024, time=2024-05-31, status=1, ipAttribution=日本), GetPortalCommentsPageByObjectIdResponse(id=2203640, encodeId=ce3e2203640b4, content=第二次投cancer letters，记录时间<br>05/05/2024 投稿<br>05/07/2024 With editor<br>05/08/2024 Under Review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ce5721017, createdName=ms3000000772221561, createdTime=Thu May 09 11:25:45 CST 2024, time=2024-05-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2195041, encodeId=fda92195041e2, content=偏重的研究方向：肿瘤<br>经验分享：请问大家这个期刊二审一般需要多久呀？我3.22提交的返修稿，今天还是Revision Submitted to Journal的状态。要毕业，有点焦急。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c266511434, createdName=科研小黑, createdTime=Sun Mar 24 17:09:24 CST 2024, time=2024-03-24, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2169383, encodeId=23cb2169383eb, content=审稿速度:1.0<br>偏重的研究方向：肿瘤<br>经验分享：10/21/2023 投稿<br>10/23/2023 改格式<br>10/23/2023 分配3个编辑<br>10/26/2023 Under Review<br>11/07/2023 Required Reviews Completed<br>11/10/2023 Decision in Process<br>11/13/2023 Major Revision 给了1个月修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ce5721017, createdName=ms3000000772221561, createdTime=Sat Nov 18 21:22:58 CST 2023, time=2023-11-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2163363, encodeId=3945216336305, content=偏重的研究方向：肿瘤<br>经验分享：09.24投稿， 10.02修改格式， 10.04 with editor， 10.17 with editor 是不是要凉凉？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1422521109, createdName=124dcee1m79暂无昵称, createdTime=Tue Oct 17 17:10:40 CST 2023, time=2023-10-17, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=921392, encodeId=693192139203, content=审稿速度:1.0<br>偏重的研究方向：白血病<br>经验分享：月初投了一篇，昨晚收到邮件分配稿号，今早登录系统一看，Decision in process，那感觉。。。。太提神了。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200618/4c27fa23bb6a44a49a51871bc8fe6190/d1c485af61c8460ba037d35b90d34b04.jpg, createdBy=e5c95263798, createdName=嚯嚯嚯1971, createdTime=Sat Jan 30 15:57:20 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114616, encodeId=19812114616ba, content=我想问一下注册cancer letters 账号的时候title一栏应该填什么啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13335609339, createdName=ms5000002011942975, createdTime=Tue Feb 14 19:24:48 CST 2023, time=2023-02-14, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2091659, encodeId=19db209165937, content=求助，爱思维尔登录注册界面登录卡死怎么解决，一直注册不了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e83e5631686, createdName=雨落殇殇, createdTime=Mon Oct 03 23:21:05 CST 2022, time=2022-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184614, encodeId=85ed218461406, content=刚投稿，血液肿瘤分子检测方向，不知道在不在期刊领域内；必须要提供推荐的审稿人，所有共同作者均需要邮件链接确认作者身份。提交完了之后很快under review，之后只更新了日期不更新状态。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78c76200857, createdName=195092_8956, createdTime=Mon Jan 29 11:53:34 CST 2024, time=2024-01-29, status=1, ipAttribution=香港)]
    2024-05-31 bluuna_ 来自日本

    审稿速度:1.0
    偏重的研究方向：肿瘤;耐药
    经验分享：第一次投cancer letters： 肺癌靶向药方向 2024.04.27 With editor 2024.04.30 Under review 2024.05.26 Required review complete 2024.05.26 Decision in process 2024.05.29 Major revision

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2173638, encodeId=cad121e3638b6, content=大家都是多久收到Proof？接收2周了，还没收到消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=189d5691892, createdName=ms7000000196819746, createdTime=Fri Dec 08 08:16:04 CST 2023, time=2023-12-08, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2207568, encodeId=2525220e5681e, content=审稿速度:1.0<br>偏重的研究方向：肿瘤;耐药<br>经验分享：第一次投cancer letters： 肺癌靶向药方向 2024.04.27 With editor 2024.04.30 Under review 2024.05.26 Required review complete 2024.05.26 Decision in process 2024.05.29 Major revision, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202404/cb60946bd398482cbee0ea0aef57ca2d-aebSZIWD78iz.jpg, createdBy=7b889196222, createdName=bluuna_, createdTime=Fri May 31 01:06:47 CST 2024, time=2024-05-31, status=1, ipAttribution=日本), GetPortalCommentsPageByObjectIdResponse(id=2203640, encodeId=ce3e2203640b4, content=第二次投cancer letters，记录时间<br>05/05/2024 投稿<br>05/07/2024 With editor<br>05/08/2024 Under Review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ce5721017, createdName=ms3000000772221561, createdTime=Thu May 09 11:25:45 CST 2024, time=2024-05-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2195041, encodeId=fda92195041e2, content=偏重的研究方向：肿瘤<br>经验分享：请问大家这个期刊二审一般需要多久呀？我3.22提交的返修稿，今天还是Revision Submitted to Journal的状态。要毕业，有点焦急。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c266511434, createdName=科研小黑, createdTime=Sun Mar 24 17:09:24 CST 2024, time=2024-03-24, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2169383, encodeId=23cb2169383eb, content=审稿速度:1.0<br>偏重的研究方向：肿瘤<br>经验分享：10/21/2023 投稿<br>10/23/2023 改格式<br>10/23/2023 分配3个编辑<br>10/26/2023 Under Review<br>11/07/2023 Required Reviews Completed<br>11/10/2023 Decision in Process<br>11/13/2023 Major Revision 给了1个月修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ce5721017, createdName=ms3000000772221561, createdTime=Sat Nov 18 21:22:58 CST 2023, time=2023-11-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2163363, encodeId=3945216336305, content=偏重的研究方向：肿瘤<br>经验分享：09.24投稿， 10.02修改格式， 10.04 with editor， 10.17 with editor 是不是要凉凉？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1422521109, createdName=124dcee1m79暂无昵称, createdTime=Tue Oct 17 17:10:40 CST 2023, time=2023-10-17, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=921392, encodeId=693192139203, content=审稿速度:1.0<br>偏重的研究方向：白血病<br>经验分享：月初投了一篇，昨晚收到邮件分配稿号，今早登录系统一看，Decision in process，那感觉。。。。太提神了。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200618/4c27fa23bb6a44a49a51871bc8fe6190/d1c485af61c8460ba037d35b90d34b04.jpg, createdBy=e5c95263798, createdName=嚯嚯嚯1971, createdTime=Sat Jan 30 15:57:20 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114616, encodeId=19812114616ba, content=我想问一下注册cancer letters 账号的时候title一栏应该填什么啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13335609339, createdName=ms5000002011942975, createdTime=Tue Feb 14 19:24:48 CST 2023, time=2023-02-14, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2091659, encodeId=19db209165937, content=求助，爱思维尔登录注册界面登录卡死怎么解决，一直注册不了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e83e5631686, createdName=雨落殇殇, createdTime=Mon Oct 03 23:21:05 CST 2022, time=2022-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184614, encodeId=85ed218461406, content=刚投稿，血液肿瘤分子检测方向，不知道在不在期刊领域内；必须要提供推荐的审稿人，所有共同作者均需要邮件链接确认作者身份。提交完了之后很快under review，之后只更新了日期不更新状态。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78c76200857, createdName=195092_8956, createdTime=Mon Jan 29 11:53:34 CST 2024, time=2024-01-29, status=1, ipAttribution=香港)]
    2024-05-09 ms3000000772221561 来自上海

    第二次投cancer letters，记录时间
    05/05/2024 投稿
    05/07/2024 With editor
    05/08/2024 Under Review

    3

    展开3条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2173638, encodeId=cad121e3638b6, content=大家都是多久收到Proof？接收2周了，还没收到消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=189d5691892, createdName=ms7000000196819746, createdTime=Fri Dec 08 08:16:04 CST 2023, time=2023-12-08, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2207568, encodeId=2525220e5681e, content=审稿速度:1.0<br>偏重的研究方向：肿瘤;耐药<br>经验分享：第一次投cancer letters： 肺癌靶向药方向 2024.04.27 With editor 2024.04.30 Under review 2024.05.26 Required review complete 2024.05.26 Decision in process 2024.05.29 Major revision, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202404/cb60946bd398482cbee0ea0aef57ca2d-aebSZIWD78iz.jpg, createdBy=7b889196222, createdName=bluuna_, createdTime=Fri May 31 01:06:47 CST 2024, time=2024-05-31, status=1, ipAttribution=日本), GetPortalCommentsPageByObjectIdResponse(id=2203640, encodeId=ce3e2203640b4, content=第二次投cancer letters，记录时间<br>05/05/2024 投稿<br>05/07/2024 With editor<br>05/08/2024 Under Review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ce5721017, createdName=ms3000000772221561, createdTime=Thu May 09 11:25:45 CST 2024, time=2024-05-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2195041, encodeId=fda92195041e2, content=偏重的研究方向：肿瘤<br>经验分享：请问大家这个期刊二审一般需要多久呀？我3.22提交的返修稿，今天还是Revision Submitted to Journal的状态。要毕业，有点焦急。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c266511434, createdName=科研小黑, createdTime=Sun Mar 24 17:09:24 CST 2024, time=2024-03-24, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2169383, encodeId=23cb2169383eb, content=审稿速度:1.0<br>偏重的研究方向：肿瘤<br>经验分享：10/21/2023 投稿<br>10/23/2023 改格式<br>10/23/2023 分配3个编辑<br>10/26/2023 Under Review<br>11/07/2023 Required Reviews Completed<br>11/10/2023 Decision in Process<br>11/13/2023 Major Revision 给了1个月修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ce5721017, createdName=ms3000000772221561, createdTime=Sat Nov 18 21:22:58 CST 2023, time=2023-11-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2163363, encodeId=3945216336305, content=偏重的研究方向：肿瘤<br>经验分享：09.24投稿， 10.02修改格式， 10.04 with editor， 10.17 with editor 是不是要凉凉？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1422521109, createdName=124dcee1m79暂无昵称, createdTime=Tue Oct 17 17:10:40 CST 2023, time=2023-10-17, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=921392, encodeId=693192139203, content=审稿速度:1.0<br>偏重的研究方向：白血病<br>经验分享：月初投了一篇，昨晚收到邮件分配稿号，今早登录系统一看，Decision in process，那感觉。。。。太提神了。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200618/4c27fa23bb6a44a49a51871bc8fe6190/d1c485af61c8460ba037d35b90d34b04.jpg, createdBy=e5c95263798, createdName=嚯嚯嚯1971, createdTime=Sat Jan 30 15:57:20 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114616, encodeId=19812114616ba, content=我想问一下注册cancer letters 账号的时候title一栏应该填什么啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13335609339, createdName=ms5000002011942975, createdTime=Tue Feb 14 19:24:48 CST 2023, time=2023-02-14, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2091659, encodeId=19db209165937, content=求助，爱思维尔登录注册界面登录卡死怎么解决，一直注册不了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e83e5631686, createdName=雨落殇殇, createdTime=Mon Oct 03 23:21:05 CST 2022, time=2022-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184614, encodeId=85ed218461406, content=刚投稿，血液肿瘤分子检测方向，不知道在不在期刊领域内；必须要提供推荐的审稿人，所有共同作者均需要邮件链接确认作者身份。提交完了之后很快under review，之后只更新了日期不更新状态。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78c76200857, createdName=195092_8956, createdTime=Mon Jan 29 11:53:34 CST 2024, time=2024-01-29, status=1, ipAttribution=香港)]
    2024-03-24 科研小黑 来自湖北省

    偏重的研究方向：肿瘤
    经验分享：请问大家这个期刊二审一般需要多久呀？我3.22提交的返修稿，今天还是Revision Submitted to Journal的状态。要毕业，有点焦急。。。

    2

    展开2条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2173638, encodeId=cad121e3638b6, content=大家都是多久收到Proof？接收2周了，还没收到消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=189d5691892, createdName=ms7000000196819746, createdTime=Fri Dec 08 08:16:04 CST 2023, time=2023-12-08, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2207568, encodeId=2525220e5681e, content=审稿速度:1.0<br>偏重的研究方向：肿瘤;耐药<br>经验分享：第一次投cancer letters： 肺癌靶向药方向 2024.04.27 With editor 2024.04.30 Under review 2024.05.26 Required review complete 2024.05.26 Decision in process 2024.05.29 Major revision, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202404/cb60946bd398482cbee0ea0aef57ca2d-aebSZIWD78iz.jpg, createdBy=7b889196222, createdName=bluuna_, createdTime=Fri May 31 01:06:47 CST 2024, time=2024-05-31, status=1, ipAttribution=日本), GetPortalCommentsPageByObjectIdResponse(id=2203640, encodeId=ce3e2203640b4, content=第二次投cancer letters，记录时间<br>05/05/2024 投稿<br>05/07/2024 With editor<br>05/08/2024 Under Review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ce5721017, createdName=ms3000000772221561, createdTime=Thu May 09 11:25:45 CST 2024, time=2024-05-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2195041, encodeId=fda92195041e2, content=偏重的研究方向：肿瘤<br>经验分享：请问大家这个期刊二审一般需要多久呀？我3.22提交的返修稿，今天还是Revision Submitted to Journal的状态。要毕业，有点焦急。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c266511434, createdName=科研小黑, createdTime=Sun Mar 24 17:09:24 CST 2024, time=2024-03-24, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2169383, encodeId=23cb2169383eb, content=审稿速度:1.0<br>偏重的研究方向：肿瘤<br>经验分享：10/21/2023 投稿<br>10/23/2023 改格式<br>10/23/2023 分配3个编辑<br>10/26/2023 Under Review<br>11/07/2023 Required Reviews Completed<br>11/10/2023 Decision in Process<br>11/13/2023 Major Revision 给了1个月修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ce5721017, createdName=ms3000000772221561, createdTime=Sat Nov 18 21:22:58 CST 2023, time=2023-11-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2163363, encodeId=3945216336305, content=偏重的研究方向：肿瘤<br>经验分享：09.24投稿， 10.02修改格式， 10.04 with editor， 10.17 with editor 是不是要凉凉？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1422521109, createdName=124dcee1m79暂无昵称, createdTime=Tue Oct 17 17:10:40 CST 2023, time=2023-10-17, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=921392, encodeId=693192139203, content=审稿速度:1.0<br>偏重的研究方向：白血病<br>经验分享：月初投了一篇，昨晚收到邮件分配稿号，今早登录系统一看，Decision in process，那感觉。。。。太提神了。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200618/4c27fa23bb6a44a49a51871bc8fe6190/d1c485af61c8460ba037d35b90d34b04.jpg, createdBy=e5c95263798, createdName=嚯嚯嚯1971, createdTime=Sat Jan 30 15:57:20 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114616, encodeId=19812114616ba, content=我想问一下注册cancer letters 账号的时候title一栏应该填什么啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13335609339, createdName=ms5000002011942975, createdTime=Tue Feb 14 19:24:48 CST 2023, time=2023-02-14, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2091659, encodeId=19db209165937, content=求助，爱思维尔登录注册界面登录卡死怎么解决，一直注册不了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e83e5631686, createdName=雨落殇殇, createdTime=Mon Oct 03 23:21:05 CST 2022, time=2022-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184614, encodeId=85ed218461406, content=刚投稿，血液肿瘤分子检测方向，不知道在不在期刊领域内；必须要提供推荐的审稿人，所有共同作者均需要邮件链接确认作者身份。提交完了之后很快under review，之后只更新了日期不更新状态。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78c76200857, createdName=195092_8956, createdTime=Mon Jan 29 11:53:34 CST 2024, time=2024-01-29, status=1, ipAttribution=香港)]
    2023-11-18 ms3000000772221561 来自上海

    审稿速度:1.0
    偏重的研究方向：肿瘤
    经验分享：10/21/2023 投稿
    10/23/2023 改格式
    10/23/2023 分配3个编辑
    10/26/2023 Under Review
    11/07/2023 Required Reviews Completed
    11/10/2023 Decision in Process
    11/13/2023 Major Revision 给了1个月修

    7

    展开7条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2173638, encodeId=cad121e3638b6, content=大家都是多久收到Proof？接收2周了，还没收到消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=189d5691892, createdName=ms7000000196819746, createdTime=Fri Dec 08 08:16:04 CST 2023, time=2023-12-08, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2207568, encodeId=2525220e5681e, content=审稿速度:1.0<br>偏重的研究方向：肿瘤;耐药<br>经验分享：第一次投cancer letters： 肺癌靶向药方向 2024.04.27 With editor 2024.04.30 Under review 2024.05.26 Required review complete 2024.05.26 Decision in process 2024.05.29 Major revision, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202404/cb60946bd398482cbee0ea0aef57ca2d-aebSZIWD78iz.jpg, createdBy=7b889196222, createdName=bluuna_, createdTime=Fri May 31 01:06:47 CST 2024, time=2024-05-31, status=1, ipAttribution=日本), GetPortalCommentsPageByObjectIdResponse(id=2203640, encodeId=ce3e2203640b4, content=第二次投cancer letters，记录时间<br>05/05/2024 投稿<br>05/07/2024 With editor<br>05/08/2024 Under Review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ce5721017, createdName=ms3000000772221561, createdTime=Thu May 09 11:25:45 CST 2024, time=2024-05-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2195041, encodeId=fda92195041e2, content=偏重的研究方向：肿瘤<br>经验分享：请问大家这个期刊二审一般需要多久呀？我3.22提交的返修稿，今天还是Revision Submitted to Journal的状态。要毕业，有点焦急。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c266511434, createdName=科研小黑, createdTime=Sun Mar 24 17:09:24 CST 2024, time=2024-03-24, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2169383, encodeId=23cb2169383eb, content=审稿速度:1.0<br>偏重的研究方向：肿瘤<br>经验分享：10/21/2023 投稿<br>10/23/2023 改格式<br>10/23/2023 分配3个编辑<br>10/26/2023 Under Review<br>11/07/2023 Required Reviews Completed<br>11/10/2023 Decision in Process<br>11/13/2023 Major Revision 给了1个月修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ce5721017, createdName=ms3000000772221561, createdTime=Sat Nov 18 21:22:58 CST 2023, time=2023-11-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2163363, encodeId=3945216336305, content=偏重的研究方向：肿瘤<br>经验分享：09.24投稿， 10.02修改格式， 10.04 with editor， 10.17 with editor 是不是要凉凉？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1422521109, createdName=124dcee1m79暂无昵称, createdTime=Tue Oct 17 17:10:40 CST 2023, time=2023-10-17, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=921392, encodeId=693192139203, content=审稿速度:1.0<br>偏重的研究方向：白血病<br>经验分享：月初投了一篇，昨晚收到邮件分配稿号，今早登录系统一看，Decision in process，那感觉。。。。太提神了。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200618/4c27fa23bb6a44a49a51871bc8fe6190/d1c485af61c8460ba037d35b90d34b04.jpg, createdBy=e5c95263798, createdName=嚯嚯嚯1971, createdTime=Sat Jan 30 15:57:20 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114616, encodeId=19812114616ba, content=我想问一下注册cancer letters 账号的时候title一栏应该填什么啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13335609339, createdName=ms5000002011942975, createdTime=Tue Feb 14 19:24:48 CST 2023, time=2023-02-14, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2091659, encodeId=19db209165937, content=求助，爱思维尔登录注册界面登录卡死怎么解决，一直注册不了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e83e5631686, createdName=雨落殇殇, createdTime=Mon Oct 03 23:21:05 CST 2022, time=2022-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184614, encodeId=85ed218461406, content=刚投稿，血液肿瘤分子检测方向，不知道在不在期刊领域内；必须要提供推荐的审稿人，所有共同作者均需要邮件链接确认作者身份。提交完了之后很快under review，之后只更新了日期不更新状态。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78c76200857, createdName=195092_8956, createdTime=Mon Jan 29 11:53:34 CST 2024, time=2024-01-29, status=1, ipAttribution=香港)]
    2023-10-17 124dcee1m79暂无昵称 来自重庆

    偏重的研究方向：肿瘤
    经验分享：09.24投稿， 10.02修改格式， 10.04 with editor， 10.17 with editor 是不是要凉凉？

    6

    展开6条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2173638, encodeId=cad121e3638b6, content=大家都是多久收到Proof？接收2周了，还没收到消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=189d5691892, createdName=ms7000000196819746, createdTime=Fri Dec 08 08:16:04 CST 2023, time=2023-12-08, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2207568, encodeId=2525220e5681e, content=审稿速度:1.0<br>偏重的研究方向：肿瘤;耐药<br>经验分享：第一次投cancer letters： 肺癌靶向药方向 2024.04.27 With editor 2024.04.30 Under review 2024.05.26 Required review complete 2024.05.26 Decision in process 2024.05.29 Major revision, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202404/cb60946bd398482cbee0ea0aef57ca2d-aebSZIWD78iz.jpg, createdBy=7b889196222, createdName=bluuna_, createdTime=Fri May 31 01:06:47 CST 2024, time=2024-05-31, status=1, ipAttribution=日本), GetPortalCommentsPageByObjectIdResponse(id=2203640, encodeId=ce3e2203640b4, content=第二次投cancer letters，记录时间<br>05/05/2024 投稿<br>05/07/2024 With editor<br>05/08/2024 Under Review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ce5721017, createdName=ms3000000772221561, createdTime=Thu May 09 11:25:45 CST 2024, time=2024-05-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2195041, encodeId=fda92195041e2, content=偏重的研究方向：肿瘤<br>经验分享：请问大家这个期刊二审一般需要多久呀？我3.22提交的返修稿，今天还是Revision Submitted to Journal的状态。要毕业，有点焦急。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c266511434, createdName=科研小黑, createdTime=Sun Mar 24 17:09:24 CST 2024, time=2024-03-24, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2169383, encodeId=23cb2169383eb, content=审稿速度:1.0<br>偏重的研究方向：肿瘤<br>经验分享：10/21/2023 投稿<br>10/23/2023 改格式<br>10/23/2023 分配3个编辑<br>10/26/2023 Under Review<br>11/07/2023 Required Reviews Completed<br>11/10/2023 Decision in Process<br>11/13/2023 Major Revision 给了1个月修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ce5721017, createdName=ms3000000772221561, createdTime=Sat Nov 18 21:22:58 CST 2023, time=2023-11-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2163363, encodeId=3945216336305, content=偏重的研究方向：肿瘤<br>经验分享：09.24投稿， 10.02修改格式， 10.04 with editor， 10.17 with editor 是不是要凉凉？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1422521109, createdName=124dcee1m79暂无昵称, createdTime=Tue Oct 17 17:10:40 CST 2023, time=2023-10-17, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=921392, encodeId=693192139203, content=审稿速度:1.0<br>偏重的研究方向：白血病<br>经验分享：月初投了一篇，昨晚收到邮件分配稿号，今早登录系统一看，Decision in process，那感觉。。。。太提神了。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200618/4c27fa23bb6a44a49a51871bc8fe6190/d1c485af61c8460ba037d35b90d34b04.jpg, createdBy=e5c95263798, createdName=嚯嚯嚯1971, createdTime=Sat Jan 30 15:57:20 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114616, encodeId=19812114616ba, content=我想问一下注册cancer letters 账号的时候title一栏应该填什么啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13335609339, createdName=ms5000002011942975, createdTime=Tue Feb 14 19:24:48 CST 2023, time=2023-02-14, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2091659, encodeId=19db209165937, content=求助，爱思维尔登录注册界面登录卡死怎么解决，一直注册不了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e83e5631686, createdName=雨落殇殇, createdTime=Mon Oct 03 23:21:05 CST 2022, time=2022-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184614, encodeId=85ed218461406, content=刚投稿，血液肿瘤分子检测方向，不知道在不在期刊领域内；必须要提供推荐的审稿人，所有共同作者均需要邮件链接确认作者身份。提交完了之后很快under review，之后只更新了日期不更新状态。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78c76200857, createdName=195092_8956, createdTime=Mon Jan 29 11:53:34 CST 2024, time=2024-01-29, status=1, ipAttribution=香港)]
    2021-01-30 嚯嚯嚯1971

    审稿速度:1.0
    偏重的研究方向：白血病
    经验分享：月初投了一篇，昨晚收到邮件分配稿号，今早登录系统一看，Decision in process，那感觉。。。。太提神了。。。。

    13

    展开13条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2173638, encodeId=cad121e3638b6, content=大家都是多久收到Proof？接收2周了，还没收到消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=189d5691892, createdName=ms7000000196819746, createdTime=Fri Dec 08 08:16:04 CST 2023, time=2023-12-08, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2207568, encodeId=2525220e5681e, content=审稿速度:1.0<br>偏重的研究方向：肿瘤;耐药<br>经验分享：第一次投cancer letters： 肺癌靶向药方向 2024.04.27 With editor 2024.04.30 Under review 2024.05.26 Required review complete 2024.05.26 Decision in process 2024.05.29 Major revision, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202404/cb60946bd398482cbee0ea0aef57ca2d-aebSZIWD78iz.jpg, createdBy=7b889196222, createdName=bluuna_, createdTime=Fri May 31 01:06:47 CST 2024, time=2024-05-31, status=1, ipAttribution=日本), GetPortalCommentsPageByObjectIdResponse(id=2203640, encodeId=ce3e2203640b4, content=第二次投cancer letters，记录时间<br>05/05/2024 投稿<br>05/07/2024 With editor<br>05/08/2024 Under Review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ce5721017, createdName=ms3000000772221561, createdTime=Thu May 09 11:25:45 CST 2024, time=2024-05-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2195041, encodeId=fda92195041e2, content=偏重的研究方向：肿瘤<br>经验分享：请问大家这个期刊二审一般需要多久呀？我3.22提交的返修稿，今天还是Revision Submitted to Journal的状态。要毕业，有点焦急。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c266511434, createdName=科研小黑, createdTime=Sun Mar 24 17:09:24 CST 2024, time=2024-03-24, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2169383, encodeId=23cb2169383eb, content=审稿速度:1.0<br>偏重的研究方向：肿瘤<br>经验分享：10/21/2023 投稿<br>10/23/2023 改格式<br>10/23/2023 分配3个编辑<br>10/26/2023 Under Review<br>11/07/2023 Required Reviews Completed<br>11/10/2023 Decision in Process<br>11/13/2023 Major Revision 给了1个月修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ce5721017, createdName=ms3000000772221561, createdTime=Sat Nov 18 21:22:58 CST 2023, time=2023-11-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2163363, encodeId=3945216336305, content=偏重的研究方向：肿瘤<br>经验分享：09.24投稿， 10.02修改格式， 10.04 with editor， 10.17 with editor 是不是要凉凉？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1422521109, createdName=124dcee1m79暂无昵称, createdTime=Tue Oct 17 17:10:40 CST 2023, time=2023-10-17, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=921392, encodeId=693192139203, content=审稿速度:1.0<br>偏重的研究方向：白血病<br>经验分享：月初投了一篇，昨晚收到邮件分配稿号，今早登录系统一看，Decision in process，那感觉。。。。太提神了。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200618/4c27fa23bb6a44a49a51871bc8fe6190/d1c485af61c8460ba037d35b90d34b04.jpg, createdBy=e5c95263798, createdName=嚯嚯嚯1971, createdTime=Sat Jan 30 15:57:20 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114616, encodeId=19812114616ba, content=我想问一下注册cancer letters 账号的时候title一栏应该填什么啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13335609339, createdName=ms5000002011942975, createdTime=Tue Feb 14 19:24:48 CST 2023, time=2023-02-14, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2091659, encodeId=19db209165937, content=求助，爱思维尔登录注册界面登录卡死怎么解决，一直注册不了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e83e5631686, createdName=雨落殇殇, createdTime=Mon Oct 03 23:21:05 CST 2022, time=2022-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184614, encodeId=85ed218461406, content=刚投稿，血液肿瘤分子检测方向，不知道在不在期刊领域内；必须要提供推荐的审稿人，所有共同作者均需要邮件链接确认作者身份。提交完了之后很快under review，之后只更新了日期不更新状态。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78c76200857, createdName=195092_8956, createdTime=Mon Jan 29 11:53:34 CST 2024, time=2024-01-29, status=1, ipAttribution=香港)]
    2023-02-14 ms5000002011942975 来自河南省

    我想问一下注册cancer letters 账号的时候title一栏应该填什么啊？

    1

    展开1条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2173638, encodeId=cad121e3638b6, content=大家都是多久收到Proof？接收2周了，还没收到消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=189d5691892, createdName=ms7000000196819746, createdTime=Fri Dec 08 08:16:04 CST 2023, time=2023-12-08, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2207568, encodeId=2525220e5681e, content=审稿速度:1.0<br>偏重的研究方向：肿瘤;耐药<br>经验分享：第一次投cancer letters： 肺癌靶向药方向 2024.04.27 With editor 2024.04.30 Under review 2024.05.26 Required review complete 2024.05.26 Decision in process 2024.05.29 Major revision, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202404/cb60946bd398482cbee0ea0aef57ca2d-aebSZIWD78iz.jpg, createdBy=7b889196222, createdName=bluuna_, createdTime=Fri May 31 01:06:47 CST 2024, time=2024-05-31, status=1, ipAttribution=日本), GetPortalCommentsPageByObjectIdResponse(id=2203640, encodeId=ce3e2203640b4, content=第二次投cancer letters，记录时间<br>05/05/2024 投稿<br>05/07/2024 With editor<br>05/08/2024 Under Review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ce5721017, createdName=ms3000000772221561, createdTime=Thu May 09 11:25:45 CST 2024, time=2024-05-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2195041, encodeId=fda92195041e2, content=偏重的研究方向：肿瘤<br>经验分享：请问大家这个期刊二审一般需要多久呀？我3.22提交的返修稿，今天还是Revision Submitted to Journal的状态。要毕业，有点焦急。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c266511434, createdName=科研小黑, createdTime=Sun Mar 24 17:09:24 CST 2024, time=2024-03-24, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2169383, encodeId=23cb2169383eb, content=审稿速度:1.0<br>偏重的研究方向：肿瘤<br>经验分享：10/21/2023 投稿<br>10/23/2023 改格式<br>10/23/2023 分配3个编辑<br>10/26/2023 Under Review<br>11/07/2023 Required Reviews Completed<br>11/10/2023 Decision in Process<br>11/13/2023 Major Revision 给了1个月修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ce5721017, createdName=ms3000000772221561, createdTime=Sat Nov 18 21:22:58 CST 2023, time=2023-11-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2163363, encodeId=3945216336305, content=偏重的研究方向：肿瘤<br>经验分享：09.24投稿， 10.02修改格式， 10.04 with editor， 10.17 with editor 是不是要凉凉？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1422521109, createdName=124dcee1m79暂无昵称, createdTime=Tue Oct 17 17:10:40 CST 2023, time=2023-10-17, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=921392, encodeId=693192139203, content=审稿速度:1.0<br>偏重的研究方向：白血病<br>经验分享：月初投了一篇，昨晚收到邮件分配稿号，今早登录系统一看，Decision in process，那感觉。。。。太提神了。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200618/4c27fa23bb6a44a49a51871bc8fe6190/d1c485af61c8460ba037d35b90d34b04.jpg, createdBy=e5c95263798, createdName=嚯嚯嚯1971, createdTime=Sat Jan 30 15:57:20 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114616, encodeId=19812114616ba, content=我想问一下注册cancer letters 账号的时候title一栏应该填什么啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13335609339, createdName=ms5000002011942975, createdTime=Tue Feb 14 19:24:48 CST 2023, time=2023-02-14, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2091659, encodeId=19db209165937, content=求助，爱思维尔登录注册界面登录卡死怎么解决，一直注册不了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e83e5631686, createdName=雨落殇殇, createdTime=Mon Oct 03 23:21:05 CST 2022, time=2022-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184614, encodeId=85ed218461406, content=刚投稿，血液肿瘤分子检测方向，不知道在不在期刊领域内；必须要提供推荐的审稿人，所有共同作者均需要邮件链接确认作者身份。提交完了之后很快under review，之后只更新了日期不更新状态。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78c76200857, createdName=195092_8956, createdTime=Mon Jan 29 11:53:34 CST 2024, time=2024-01-29, status=1, ipAttribution=香港)]
    2022-10-03 雨落殇殇

    求助，爱思维尔登录注册界面登录卡死怎么解决，一直注册不了

    2

    展开2条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2173638, encodeId=cad121e3638b6, content=大家都是多久收到Proof？接收2周了，还没收到消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=189d5691892, createdName=ms7000000196819746, createdTime=Fri Dec 08 08:16:04 CST 2023, time=2023-12-08, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2207568, encodeId=2525220e5681e, content=审稿速度:1.0<br>偏重的研究方向：肿瘤;耐药<br>经验分享：第一次投cancer letters： 肺癌靶向药方向 2024.04.27 With editor 2024.04.30 Under review 2024.05.26 Required review complete 2024.05.26 Decision in process 2024.05.29 Major revision, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202404/cb60946bd398482cbee0ea0aef57ca2d-aebSZIWD78iz.jpg, createdBy=7b889196222, createdName=bluuna_, createdTime=Fri May 31 01:06:47 CST 2024, time=2024-05-31, status=1, ipAttribution=日本), GetPortalCommentsPageByObjectIdResponse(id=2203640, encodeId=ce3e2203640b4, content=第二次投cancer letters，记录时间<br>05/05/2024 投稿<br>05/07/2024 With editor<br>05/08/2024 Under Review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=10, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ce5721017, createdName=ms3000000772221561, createdTime=Thu May 09 11:25:45 CST 2024, time=2024-05-09, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2195041, encodeId=fda92195041e2, content=偏重的研究方向：肿瘤<br>经验分享：请问大家这个期刊二审一般需要多久呀？我3.22提交的返修稿，今天还是Revision Submitted to Journal的状态。要毕业，有点焦急。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c266511434, createdName=科研小黑, createdTime=Sun Mar 24 17:09:24 CST 2024, time=2024-03-24, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2169383, encodeId=23cb2169383eb, content=审稿速度:1.0<br>偏重的研究方向：肿瘤<br>经验分享：10/21/2023 投稿<br>10/23/2023 改格式<br>10/23/2023 分配3个编辑<br>10/26/2023 Under Review<br>11/07/2023 Required Reviews Completed<br>11/10/2023 Decision in Process<br>11/13/2023 Major Revision 给了1个月修, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ce5721017, createdName=ms3000000772221561, createdTime=Sat Nov 18 21:22:58 CST 2023, time=2023-11-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2163363, encodeId=3945216336305, content=偏重的研究方向：肿瘤<br>经验分享：09.24投稿， 10.02修改格式， 10.04 with editor， 10.17 with editor 是不是要凉凉？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1422521109, createdName=124dcee1m79暂无昵称, createdTime=Tue Oct 17 17:10:40 CST 2023, time=2023-10-17, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=921392, encodeId=693192139203, content=审稿速度:1.0<br>偏重的研究方向：白血病<br>经验分享：月初投了一篇，昨晚收到邮件分配稿号，今早登录系统一看，Decision in process，那感觉。。。。太提神了。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200618/4c27fa23bb6a44a49a51871bc8fe6190/d1c485af61c8460ba037d35b90d34b04.jpg, createdBy=e5c95263798, createdName=嚯嚯嚯1971, createdTime=Sat Jan 30 15:57:20 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114616, encodeId=19812114616ba, content=我想问一下注册cancer letters 账号的时候title一栏应该填什么啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13335609339, createdName=ms5000002011942975, createdTime=Tue Feb 14 19:24:48 CST 2023, time=2023-02-14, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2091659, encodeId=19db209165937, content=求助，爱思维尔登录注册界面登录卡死怎么解决，一直注册不了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e83e5631686, createdName=雨落殇殇, createdTime=Mon Oct 03 23:21:05 CST 2022, time=2022-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184614, encodeId=85ed218461406, content=刚投稿，血液肿瘤分子检测方向，不知道在不在期刊领域内；必须要提供推荐的审稿人，所有共同作者均需要邮件链接确认作者身份。提交完了之后很快under review，之后只更新了日期不更新状态。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78c76200857, createdName=195092_8956, createdTime=Mon Jan 29 11:53:34 CST 2024, time=2024-01-29, status=1, ipAttribution=香港)]
    2024-01-29 195092_8956 来自香港

    刚投稿，血液肿瘤分子检测方向，不知道在不在期刊领域内；必须要提供推荐的审稿人，所有共同作者均需要邮件链接确认作者身份。提交完了之后很快under review，之后只更新了日期不更新状态。

    2

    展开2条回复
共500条页码: 1/50页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分